Баранская Е.К. Синдром раздраженного кишечника: диагностика и лечение. Consilium medicum, 2000, 2(7).
Locke GR, III, Zinsmeister A, Talley NJ, Fett SL, Melton J. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc, 2000, 75: 907-912.
Баранская Е.К. Синдром раздраженного кишечника: диагностика и лечение. Consilium medicum, 2002, 4(9).
Costanza C, Longstreth G, Liu A. Chronic abdominal wall pain: clinical features, health care costs, and long-term outcome. Clin Gastroenterol Hepatol, 2004, 2: 395-399.
Маев И.В., Черемушкин С.В. Заболевания кишечника. Синдром раздраженного кишечника. Римские критерии III. Consilium medicum, 2007, 09(1).
Sagami Y, Shimada Y, Tayama J, Nomura T, Satake M, Endo Y, et al. Effect of a corticotrophin-releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut, 2004, 53: 958-964.
Galligan JJ, Vanner S. Basic and clinical pharmacology of new motility promoting agents 1. Neurogastroenterol Motil, 2005, 17: 643-653.
Keefer L, Sanders K, Sykes MA, Blanchard EB, Lackner JM, Krasner S. Towards a better understanding of anxiety in irritable bowel syndrome: a preliminary look at worry and intolerance of uncer tainty. J Cognitive Psychother, 2005, 19: 163-172.
Kim HJ, Camilleri M, Carlson PJ, Cremonini F, Ferber I, Stephens D, et al. Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut, 2004, 53: 829-837.
Longstreth GF, Drossman DA. Severe irritable bowel and functional abdominal pain syndromes: managing the patient and health care costs. Clin Gastroenterol Hepatol, 2005, 3: 397-400.
Whitehead WE, Delvaux M. Standardization of procedures for testing smooth muscle tone and sensory thresholds in the gastrointestinal tract. Dig Dis Sci, 1994, 42: 223-241.
Yeo A, Boyd P, Lumsden S, Saunders T, Handley A, Stubbins M, et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut, 2004, 53: 1452-14.
von Arnim U, Peitz U, Vinson B. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol, 2007, 102: 1268-75.
Buchert D. Wirksamkeit und Verträglichkeit von Iberogast bei Patienten mit gesicherter Non Ulcus Dyspepsie. Z Phytotherapie, 1994, 15(1): 45-6.
Madisch A, Melderis H, Mayr G. Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie. Z Gastroenterologie, 2001, 39: 1-8.
Braden B, Caspary W, Börner N. Clinical effects of STW 5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis. Neurogastroenterol Motil, 2009 21(6): 632-8.
Rösch W, Vinson B, Sassin I. A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z Gastroenterol, 2002, 40(6): 401-8.
Madisch A, Holtmann G, Plein K. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther, 2004, 19(3): 271-9.
Klein-Galczinsky C, Sassin I. Anwendungsbeobachtung zur Wirksamkeit und Verträglichkeit von Iberogast® in der Therapie des Colon irritabile. Phytotherapie an der Schwelle zum neuen Jahrtausend, 1999, 125.
Wagner H. Multitarget therapy: the future of treatment for more than just functional dyspepsia. Phytomedicine, 2006, 13(Suppl. 5): 122-99.